Correvio Pharma (CORV) Stock Price, News & Analysis

Company Overview

Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $0.42 to $0.42
• 50-Day Range: $0.39 to $0.42
• 52-Week Range: $0.21 to $2.79
• Volume: N/A
• Average Volume: 5.35 million shs
• Market Capitalization: $27.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CORV Stock Analysis - Frequently Asked Questions

How were Correvio Pharma's earnings last quarter?

Correvio Pharma Corp (NASDAQ:CORV) announced its earnings results on Monday, March, 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.06. The business had revenue of $11.33 million for the quarter, compared to analysts' expectations of $11.52 million. Correvio Pharma had a negative trailing twelve-month return on equity of 2,128.82% and a negative net margin of 107.81%.

What other stocks do shareholders of Correvio Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Correvio Pharma investors own include Inovio Pharmaceuticals (INO), NightHawk Biosciences (NHWK), SCYNEXIS (SCYX), Acasti Pharma (ACST), Onconova Therapeutics (ONTX), Outlook Therapeutics (OTLK) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 3/30/2020
• Today: 4/19/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CORV
• CIK: N/A
• Web: www.correvio.com
• Phone: 604-677-6905
• Fax: N/A
• Employees: 133
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,180,000.00
• Net Margins: -107.81%
• Pretax Margin: N/A
• Return on Equity: -2,128.82%
• Return on Assets: -58.56%

Debt

• Debt-to-Equity Ratio: 22.54
• Current Ratio: 1.07
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: $32.63 million
• Price / Sales: 0.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: -21.00

Miscellaneous

• Outstanding Shares: 66,191,000
• Free Float: N/A
• Market Cap: $27.80 million
• Optionable: Optionable
• Beta: 0.08